Lymphoma Research

Lymphoma Research
Information on trends in incidence and mortality in lymphoma initiatives and selected research advances.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib than patients with another molecular subtype of the disease ( 1 ) Measurement of circulating tumor DNA in blood can be used to detect disease recurrence in patients with a curable form of cancer known as diffuse large B-cell lymphoma (DLBCL). In most patients, measurement of ct DNA enabled detection of microscopic disease before it could be seen on computerized tomography scans. ( 2 ) Young patients with some types of advanced cancer, for whom standard treatment had failed, had their tumors disappear during treatment with a drug that both targets and blocks a protein associated with their disease. ( 3)


Reference: Wilson WH, Staudt LM, et al. Targeting B-Cell Receptor Signaling with Ibrutinib in Diffuse Large B-Cell Lymphoma. Nature Medicine. Online July 20, 2015. http://dx.doi.org/10.1038/nm.3884Exit Disclaimer.
Reference: Roschewski M, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncology. April 2, 2015. DOI and web link: http://dx.doi.org/10.1016/S1470-2045(15)70106-3Exit Disclaimer.
Reference: ASCO 2012 abstract #9500: Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group Phase I consortium study. Yael P. Mosse posted on may 16 2012